Illumina, Inc. (NASDAQ:ILMN) Stake Raised by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 268,441 shares of the life sciences company’s stock after purchasing an additional 481 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.17% of Illumina worth $36,862,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. WCM Investment Management LLC grew its holdings in shares of Illumina by 2,232.3% in the 1st quarter. WCM Investment Management LLC now owns 3,377,221 shares of the life sciences company’s stock worth $463,760,000 after acquiring an additional 3,232,418 shares during the last quarter. Vanguard Group Inc. increased its stake in Illumina by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock worth $2,466,614,000 after purchasing an additional 2,336,935 shares in the last quarter. Capital World Investors acquired a new stake in Illumina during the 4th quarter worth about $271,753,000. Norges Bank purchased a new stake in Illumina during the fourth quarter valued at about $264,636,000. Finally, Coatue Management LLC purchased a new stake in Illumina during the fourth quarter valued at about $119,285,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of recent analyst reports. Jefferies Financial Group initiated coverage on shares of Illumina in a report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target on the stock. Evercore ISI cut their target price on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 11th. Robert W. Baird raised their target price on Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. StockNews.com started coverage on Illumina in a research report on Sunday, June 30th. They set a “buy” rating on the stock. Finally, OTR Global restated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $157.62.

Illumina Trading Up 3.1 %

ILMN opened at $108.52 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average of $110.00 and a 200-day moving average of $126.45. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $195.64.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter in the prior year, the business earned $0.08 earnings per share. The company’s revenue was down 1.0% on a year-over-year basis. Equities analysts forecast that Illumina, Inc. will post 0.98 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.